← Pipeline & Clinical Trials

Phase 1/2 HORIZEN clinical trial

Enzomenib (DSP-5336)

Enzomenib in Relapsed/Refractory and Newly-Diagnosed Acute Leukemia

HORIZENNCT04988555

An ongoing Phase 1/2 study (NCT04988555) investigating enzomenib in patients with acute leukemia and other selected hematologic malignancies, including those with KMT2A-rearranged or NPM1-mutated subtypes, high-risk MDS, and relapsed/refractory MM

Background

Menin is a key mediator of oncogenic signaling in acute leukemias characterized by KMT2A (mixed-lineage leukemia [MLL]) rearrangements and NPM1 mutations. Enzomenib (DSP‑5336) is an investigational, orally administered menin inhibitor.

Enzomenib

Other Names

DSP-5336

Modality

Small molecule menin inhibitor (oral)

KMT2A, histone-lysine N‑methyltransferase 2A; MM, multiple myeloma; MDS, myelodysplastic syndrome; MLL, mixed-lineage leukemia; NPM1, nucleophosmin 1.

Overview

Enzomenib (DSP-5336) is currently being evaluated in adults and eligible adolescents (≥12 years who weigh ≥40 kg for monotherapy, country/site specific) with acute leukemia harboring KMT2A (MLL) rearrangements or NPM1 mutations.

The ongoing Phase 1/2 trial, A Study of DSP-5336 in Acute Leukemia and Other Selected Hematologic Malignancies, With and Without MLL Rearrangement or NPM1 Mutation is a multicenter, open-label, dose-escalation and expansion study assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of enzomenib as monotherapy and in combination regimens.

Objectives

Phase 1

Primary Objectives:

  • To evaluate the safety and tolerability of enzomenib, including AEs and SAEs
  • To determine the recommended Phase 2 dose (RP2D) based on safety (including dose-limiting toxicities), PK, and preliminary clinical response

Phase 2

Primary Objective:

  • To evaluate disease response, specifically CR and CRh

Secondary Objectives:

  • To characterize PK parameters (eg, Cmax, t1/2, AUlast)
  • To evaluate disease response, including Overall Response Rate (ORR), CRc (CR, CRh, or CRi)
  • To assess safety and tolerability (eg, AEs, SAEs)
  • To evaluate overall survival (OS)
  • To evaluate event-free survival (EFS)
  • To evaluate duration of CR/CRh and duration of response

AE, adverse events; AML, acute myeloid leukemia; AUClast, area under the curve to the last measurable concentration; Cmax, maximum observed drug concentration; CR, complete response; CRc, complete response composite; CRh, or complete remission with partial hematologic recovery; CRi, or complete remission with incomplete hematologic recovery; KMT2A, histone-lysine N‑methyltransferase 2A; MLL, mixed-lineage leukemia; NPM1, nucleophosmin 1; PK, pharmacokinetics; SAE, serious adverse events; t1/2, elimination half-life.

Study Design

The Horizen trial is a multicenter, open-label, dose-escalation and expansion Phase 1/2 study.

Monotherapy in Patients with Relapsed/Refractory (R/R) Hematologic Malignancies

R/R acute leukemia with KMT2Ar or R/R AML with NPM1m

  • Phase 1 & 2: Enzomenib with or without select azoles (depending on treatment arm)

High-risk R/R MDS after HMA or refractory MM (select sites/regions)

  • Phase 1: Enzomenib

Combination Therapy in Patients with Relapsed/Refractory Acute Leukemias

R/R acute AML with KMT2Ar or NPM1m

  • Phase 1: Enzomenib with venetoclax and azacitidine

R/R acute AML with FLT3m + NPM1m or KMT2Ar

  • Phase 1: Enzomenib with gilteritinib

Combination Therapy in Patients with Newly Diagnosed AML

AML with KMT2Ar (fit or unfit) or with NPM1m (unfit)

  • Phase 1: Enzomenib with select azoles (depending on treatment arm), venetoclax, and azacitidine

AML with KMT2Ar or NPM1m

  • Phase 1: Enzomenib with select azoles (depending on treatment arm) and intensive chemotherapy

AML, acute myeloid leukemia; FLT3m, fms-like tyrosine kinase 3 mutation; HMA, hypomethylating agent; KMT2Ar, histone-lysine N‑methyltransferase 2A rearrangement; MDS, myelodysplastic syndrome; MM, multiple myeloma; NPM1m, nucleophosmin 1 mutation; R/R, relapsed or refractory.

Eligibility

Phase-Specific Criteria

Phase 1 R/R:

  • Diagnosis of morphologically R/R acute leukemia defined as ≥1 of the following:
    • ≥5% blasts in bone marrow
    • Extramedullary disease
    • Peripheral blasts

Phase 1 Newly Diagnosed:

  • Newly diagnosed AML according to WHO 2022 guidelines with KMT2Ar or NPM1m by local assay
  • No prior treatment, except hydroxyurea or, for those with significant leukocytosis or symptoms, cytarabine (maximum 500 mg for cytoreduction)

Phase 2 R/R:

  • Diagnosis of morphologically R/R acute leukemia with ≥5% blasts in bone marrow
  • No prior menin inhibitor

Key Inclusion Criteria

  • ≥18 years old (Country/site specific: ≥12 years who weigh ≥40 kg for monotherapy)
  • ECOG performance status ≤2
  • WBC <30,000/μL for monotherapy or <25,000/μL for combination therapy
  • Adequate cardiac and organ function
  • Life expectancy ≥3 months

Key Exclusion Criteria

  • Clinically significant abnormal cardiac functions, including QTcF >480 msec (≥470/≥450 for males/females, respectively, in the UK) and LVEF <50%
  • Have an active and uncontrolled bacterial, viral or fungal infection requiring parenteral therapy
  • Have active CNS leukemia (prophylactic intrathecal chemotherapy is allowed)
  • HSCT or CAR-T within 60 days prior
  • Donor lymphocyte infusion within 28 days prior
  • Active infection, including HIV or hepatitis C or B
  • Receiving strong CYP3A4/5 inhibitors or inducers, including specifically: ketoconazole, itraconazole, and isavuconazole
  • UK sites only: receipt of live vaccine within 30 days prior to receipt of first dose
View All Criteria

AML, acute myeloid leukemia; CAR-T, chimeric antigen receptor–T cell; CNS, central nervous system; CYP3A4/5, cytochrome P450 family 3 subfamily A member 4/5; ECOG, Eastern Cooperative Oncology Group; HIV, human immunodeficiency virus; HSCT, hematopoietic stem cell transplant; KMT2Ar, histone-lysine N‑methyltransferase 2A rearrangement; LVEF, left ventricular ejection fraction; NPM1m, nucleophosmin 1 mutation; QTcF, QT interval corrected for heart rate using Fridericia's formula; R/R, relapsed or refractory; WBC, white blood cell; WHO, World Health Organization.

Endpoints

Primary Endpoints

Phase 1:

  • Safety and dose-limiting toxicities
  • Treatment-emergent adverse events
  • Determination of RP2D based on safety including dose-limiting toxicities, PK, and clinical response

Phase 2:

  • Complete response (CR) + complete response with partial hematologic recovery (CRh)

Secondary Endpoints

  • Overall response rate (ORR)
  • Complete response composite (CRc), including CR, CRh, or complete remission with incomplete hematologic recovery (CRi)
  • Duration of CR/CRh and duration of response (DOR)
  • Overall survival (OS)
  • Event-free survival (EFS)
  • Transfusion independence
  • Pharmacokinetic measures (eg, Cmax, t1/2, AUClast)
  • Further assessment of AE and SAE safety

Exploratory analyses include minimal residual disease (MRD) negativity and molecular correlates of response and resistance.

AE, adverse events; AUClast, area under the curve to the last measurable concentration; Cmax, maximum observed drug concentration; CR, complete response; CRc, complete response composite; CRh, or complete remission with partial hematologic recovery; CRi, or complete remission with incomplete hematologic recovery; PK, pharmacokinetics; RP2D, recommended phase 2 dose; SAE, serious adverse events; t1/2, elimination half-life.

Site Locations

Find a Study Site

This global study is currently enrolling across the United States, Belgium, Canada, France, Italy, Japan, Singapore, South Korea, Spain, Switzerland, Taiwan, and the United Kingdom. Enter your ZIP code or explore the map to find active sites closest to your location.

This study site locator serves as a tool to connect healthcare professionals with the most accessible study site in the area for their patients.

Enrollment

Providers should contact the center directly or the Sumitomo Pharma America, Inc. study contact for enrollment and more information.

Study Contact: Matt Hitron, MD

Looking for More Information?

Download the study information document and access the full study record, including eligibility criteria and site locations, at ClinicalTrials.gov (NCT04988555).

Contact Us

Connect with an MSL

Find a Medical Science Liaison (MSL) in your region and specialty.

Stay up to date

Sign up to receive the latest clinical data, scientific resources and news from Sumitomo Pharma America Medical Affairs.